Sunitinib Malate
FDA-approved product (capsule, oral), marketed as Sunitinib Malate, Sutent.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Clear cell renal carcinoma
- Gastrointestinal stromal tumor
- Neoplasm
- Neuroendocrine neoplasm
- Pancreatic neuroendocrine tumor
- Papillary renal cell carcinoma
- Renal cell adenocarcinoma
- Renal cell carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other protein kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Sunitinib Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer
NCT00371553 · start 2006-11
Registered record
- Registry ID
- NCT00371553
- Conditions
- Relapsed or Cisplatin-Refractory Germ Cell Cancer
- Interventions
- SU011248 (Sunitinib)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2009-06
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapsed or Cisplatin-Refractory Germ Cell CancerInterventionSU011248 (Sunitinib)PhasePhase 2Registry statusCompletedSU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
NCT00270413 · start 2006-01
Registered record
- Registry ID
- NCT00270413
- Conditions
- Metastatic Breast Cancer
- Interventions
- SU11248
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2009-03
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Breast CancerInterventionSU11248PhasePhase 2Registry statusCompletedStudy Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
NCT00511849 · start 2005-11
Registered record
- Registry ID
- NCT00511849
- Conditions
- Neoplasms
- Interventions
- carboplatin + SU011248 (sunitinib) + paclitaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2009-02
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNeoplasmsInterventioncarboplatin + SU011248 (sunitinib) + paclitaxelPhasePhase 1Registry statusCompletedStudy Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
NCT00712504 · start 2004-07
Registered record
- Registry ID
- NCT00712504
- Conditions
- Advanced Solid Tumors; Non Small Cell Lung Cancer
- Interventions
- sunitinib; docetaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2007-11
- Enrolment
- 49
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Solid Tumors; Non Small Cell Lung CancerInterventionsunitinib; docetaxelPhasePhase 1Registry statusCompletedStudying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
NCT00914043
Registered record
- Registry ID
- NCT00914043
- Conditions
- Breast Cancer; Fatigue
- Interventions
- gene expression analysis; microarray analysis; polymerase chain reaction; polymorphism analysis; reverse transcriptase-polymerase chain reaction; biologic sample preservation procedure; enzyme-linked immunosorbent assay; laboratory biomarker analysis; fatigue assessment and management
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Withdrawn
- Start
- Not recorded
- Completion
- 2010-06
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; FatigueInterventiongene expression analysis; microarray analysis; polymerase chain reaction; polymorphism analysis +5 morePhaseNot recordedRegistry statusWithdrawn